Table 1.
Characteristics of Patients Receiving Myeloablative Transplant from HLA-Identical Sibling for AML, CML, ALL, or MDS, Reported to CIBMTR between 1990 and 2007
| Characteristics of Patients | DR15(+) | DR15(−) | P value |
|---|---|---|---|
| Patient-related | |||
| Number of patients | 732 | 2159 | |
| Number of centers | 156 | 207 | |
| Age at transplantation, median (range), years | 34 (1–66) | 34 (1–71) | .298 |
| Age in decades | .365 | ||
| 0–9 | 42 (6) | 162 (8) | |
| 10–19 | 121 (17) | 347 (16) | |
| 20–29 | 143 (20) | 389 (18) | |
| 30–39 | 153 (21) | 503 (23) | |
| 40–49 | 180 (25) | 490 (23) | |
| 50–59 | 93 (13) | 268 (12) | |
| Gender | .676 | ||
| Male | 418 (57) | 1217 (56) | |
| Female | 314 (43) | 940 (44) | |
| Missing | 0 | 2 (<1) | |
| Race | .006 | ||
| White | 594 (81) | 1729 (80) | |
| African American | 29 (4) | 45 (2) | |
| Asian/Pacific Islander | 53 (7) | 132 (6) | |
| Hispanic | 34 (5) | 161 (7) | |
| Native American | 2 (<1) | 13 (<1) | |
| Other | 13 (2) | 59 (3) | |
| Unknown/missing | 7 (<1) | 20 (<1) | |
| Karnofsky score | .989 | ||
| <90% | 156 (21) | 458 (21) | |
| ≥90% | 567 (77) | 1673 (77) | |
| Missing | 9 (1) | 28 (1) | |
| Disease-related | |||
| Disease | .001 | ||
| AML | 291 (40) | 747 (35) | |
| ALL | 184 (25) | 516 (24) | |
| CML | 198 (27) | 750 (35) | |
| MDS | 59 (8) | 146 (7) | |
| Disease status at transplantation* | .879 | ||
| Early | 453 (62) | 1361 (63) | |
| Intermediate | 140 (19) | 415 (19) | |
| Advanced | 132 (18) | 366 (17) | |
| Other/unknown | 7 (<1) | 17 (<1) | |
| Transplantation-related | |||
| Common conditioning drug combinations | .974 | ||
| TBI+Cy+/−other | 249 (34) | 742 (34) | |
| TBI+/−other (no Cy) | 54 (7) | 162 (8) | |
| Cy+Bu+/−other (no TBI) | 429 (59) | 1255 (58) | |
| DR sex match | .916 | ||
| M-M | 228 (31) | 679 (31) | |
| M-F | 162 (22) | 466 (22) | |
| F-M | 191 (26) | 537 (25) | |
| F-F | 149 (20) | 471 (22) | |
| Missing | 2 (<1) | 6 (<1) | |
| D-R CMV match | .318 | ||
| Neg-Neg | 361 (49) | 1084 (50) | |
| Neg-Pos | 66 (9) | 242 (11) | |
| Pos-Pos | 103 (14) | 278 (13) | |
| Pos-Neg | 183 (25) | 490 (23) | |
| Missing | 19 (3) | 65 (3) | |
| Graft type | .167 | ||
| Bone marrow | 399 (55) | 1240 (57) | |
| Peripheral blood | 333 (45) | 919 (43) | |
| Year of transplantation | .966 | ||
| 1990–1993 | 7 (<1) | 25 (1) | |
| 1994–1997 | 245 (33) | 705 (33) | |
| 1998–2001 | 243 (33) | 722 (33) | |
| 2002–2005 | 199 (27) | 584 (27) | |
| 2006–2007 | 38 (5) | 123 (6) | |
| GVHD prophylaxis | .966 | ||
| CSA+MTX+/−other | 732 | 2159 | |
| Median follow-up of survivors, mo | 74 (1–226) | 74 (1–220) | |
AML indicates acute myelogenous leukemia; CML, chronic myelogenous leukemia; ALL, acute lymphoblastic leukemia; MDS, myelodysplastic syndrome; CIBMTR, Center for International Blood and Marrow Transplant Research; TBI, total body irradiation; Cy, cyclophosphamide; Bu, busulfan; CMV, cytomegalovirus; GVHD, graft-versus-host disease; CSA, cyclosporine; MTX, methotrexate.
Disease status is categorized as follows:
Early = AML/ALL (CR1), CML (CP1), MDS (RA/RARS/pre-HCT marrow blasts <5%);
Intermediate = AML/ALL (≥CR2), CML (AP or ≥CP2);
Advanced = AML/ALL (REL/PIF), CML in BP, MDS (RAEB/RAEB-t/CMML or marrow blasts ≥5%);
Other/unknown = everything else.